HLA-G as predisposing for metastasis

Medical Hypotheses

Volumn 77, Issue 1, 2011, Pages 134-139

  Zidi, Ines ^a   Ben Amor, Nidhal ^b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; HLA G ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CATALYST; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; METASTASIS; NATURAL KILLER CELL; PREGNANCY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; NEOPLASM METASTASIS;

EID: 79958024288     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.03.046     Document Type: Article

References (94)

1. Chiang A.C., Massagué J. Molecular Basis of Metastasis. N Engl J Med 2008, 359:2814-2823.
2. Le Gal F., Riteau B., Sedlik C., Khalil-Daher I., Menier C., Dausset J., et al. HLA-G mediated-inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999, 11:101-106.
3. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., Dausset J., Carosella E.D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc Natl Acad Sci USA 1997, 94:5249-5254.
4. Riteau B., Rouas-Freiss N., Menier C., Paul P., Dausset J., Carosella E.D. HLA-G2, -G3, and -G4 Isoforms Expressed as Nonmature Cell Surface Glycoproteins Inhibit NK and Antigen-Specific CTL Cytolysis. J Immunol 2001, 166:5018-5026.
5. Marchal-Bras-Goncalves R., Rouas-Freiss N., Connan F., Choppin J., Dausset J., Carosella E.D., et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 2001, 33:2355-2359.
6. Le Rond S., Le Maoult J., Créput C., Menier C., Deschamps M., Le Friec G., et al. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol 2004, 34:649-660.
7. Lila N., Rouas-Freiss N., Dausset J., Carpentier A., Carosella E.D. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 2001, 98:12150-12155.
8. Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 2010; doi 10.1007/s00018-010-0583-4.
9. Kanai T., Fujii T., Unno N., Yamashita T., Hyodo H., Miki A., et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol 2001, 45(2):94-99.
10. Kanai T., Fujii T., Kozuma S., Yamashita T., Miki A., Kikuchi A. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod 2001, 7(2):195-200.
11. LeMaoult J., Zafaranloo K., Le Danff C., Carosella E.D. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005, 19:662-664.
12. Moreau P., Flajollet S., Carosella E.D. Non-classical transcriptional regulation of HLA-G: an update. J cell mol med 2009, 13(98):2973-2989.
13. Rouas-Freiss N., Goncalves R.M., Menier C., Dausset J., Carosella E.D. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997, 94:11520-11525.
14. Creput C., Durrbach A., Menier C., Guettier C., Samuel D., Dausset J., et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003, 39:587-594.
15. Lila N., Amrein C., Guillemain R., Chevalier P., Latremouille C., Fabiani J.N., et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002, 105:1949-1954.
16. Rouas-Freiss N., Moreau P., Ferrone S., Carosella E.D. HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism?. Cancer Res 2005, 65:10139-10144.
17. Fainardi E, Castellazzi M, Stignani M, Morandi F, Sana G, Gonzalez R, et al. Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci 2010; doi 10.1007/s00018-010-0584-3.
18. Park G.M., Lee S., Park B., Kim E., Shin J., Cho K., et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophs Res Commun 2004, 313:606-611.
19. Sheu J., Shih I. HLA-G and immune evasion in cancer cells. J Formos Med Assoc 2010, 109(4):248-257.
20. Holtan S.M., Creedon DJ., Haluska S.R., Markovic SN., Dong D.D., Lin X.M. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009, 84(11):985-1000.
21. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D., Lin X.M. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung cancer 2007, 58(2):267-274.
22. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D., Lin X.M. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007, 14(10):2721-2729.
23. Ye S.R., Yang H., Li K., Dong D.D., Lin X.M., Yie S.M. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007, 20(3):375-383.
24. Adrián Cabestré F., Moreau P., Riteau B., Ibrahim E.C., Le Danff C., Dausset J., et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol 1999, 43(2):183-193.
25. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998, 95(8):4510-4515.
26. Drug Management of Prostate Cancer 2010, Springer, New York Dordrecht Heidelberg London. W.D. Figg, C.H. Chau, E.J. Small (Eds.).
27. Li C., Houser BL., Nicotra C., Strominger JL., et al. HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci USA 2009, 106(14):5767-5772.
28. Zidi I., Guillard C., Marcou C., Krawice-Radanne I., Sangrouber D., Rouas-Freiss N., et al. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci 2006, 63(22):2669-2681.
29. Urosevic M., Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 2003, 13(5):337-342.
30. Urosevic M., Willers J., Mueller B., Kempf W., Burg G., Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002, 99(2):609-617.
31. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001, 159(3):817-824.
32. Paul P., Cabestré F.A., Le Gal F.A., Khalil-Daher I., Le Danff C., Schmid M., et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999, 59(8):1954-1960.
33. Pistoia V., Morandi F., Wang X., Ferrone S. Soluble HLA-G: Are they clinically relevant?. Semin Cancer Biol 2007, 17(6):469-479.
34. Morandi F., Ferretti E., Bocca P., Prigione I., Raffaghello L., Pistoia V. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. PLoS One 2010, 5(7):e11763.
35. Turner H.E., Nagy Z., Esiri M.M., Harris A.L., Wass J.A. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 2000, 85(8):2931-2935.
36. Ardi V.C., Kupriyanova T.A., Deryugina E.I., Quigley J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007, 104(51):20262-20267.
37. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446(7137):765-770.
38. Park G.M., Lee S., Park B., Kim E., Shin J., Cho K., et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004, 313(3):606-611.
39. Dong Y., Lieskovska J., Kedrin D., Porcelli S., Mandelboim O., Bushkin Y. Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol 2003, 64(8):802-810.
40. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-176.
41. Chin M.P., Deen W.M. Prediction of nitric oxide concentrations in melanomas. Nitric oxide 2010, 23(4):319-326.
42. Díaz-Lagares A., Alegre E., LeMaoult J., Carosella E.D., González A. Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology 2009, 126(3):436-445.
43. Díaz-Lagares A., Alegre E., Gonzalez A. Detection of 3-nitrotyrosine-modified human leukocyte antigen-G in biological fluids. Hum Immunol 2009, 70(12):976-980.
44. González A., López A.S., Alegre E., Alcázar J.L., López-Moratalla N. Does nitric oxide play a role in maternal tolerance towards the foetus?. J Physiol Biochem 2004, 60(3):227-238.
45. Menier C., Rabreau M., Challier J.C., Le Discorde M., Carosella E.D., Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004, 104(10):3153-3160.
46. Carosella ED, Gregori S, Rouas-Freiss N, Lemaoult J, Menier C, Favier B. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 2010; doi 10.1007/s00018-010-0579-0.
47. Le Bouteiller P., Fons P., Herault J.P., Bono F., Chabot S., Cartwright J.E., et al. Soluble HLA-G and control of angiogenesis. J Reprod Immunol 2007, 76(1-2):17-22.
48. Fons P., Chabot S., Cartwright J.E., Lenfant F., L'Faqihi F., Giustiniani J., et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006, 108(8):2608-2615.
49. Wilczyński J.R. Cancer and pregnancy share similar mechanisms of immunological escape. Chemotherapy 2006, 52(3):107-110.
50. LeMaoult J., Caumartin J., Carosella E.D. Exchanges of membrane patches (trogocytosis) split theoretical and actual functions of immune cells. Hum Immunol 2007, 68(4):240-243.
51. Caumartin J., Favier B., Daouya M., Guillard C., Moreau P., Carosella E.D., et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007, 26(5):1423-1433.
52. LeMaoult J., Caumartin J., Daouya M., Favier B., Le Rond S., Gonzalez A., et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007, 109(5):2040-2048.
53. HoWangYin K., Alegre E., Daouya M., Favier B., Carosella E.D., LeMaoult J. Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci 2010, 67(7):1133-1145.
54. DeClerck K., Elble R.C. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 2010, 15:213-225.
55. Mouillot G., Marcou C., Zidi I., Guillard C., Sangrouber D., Carosella E.D., et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007, 68(4):277-285.
56. Chang C.C., Murphy S.P., Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol 2003, 64(11):1057-1063.
57. Chaput N., Schartz N.E., Andre F., Zitvogel L. Exosomes for immunotherapy of cancer. Adv Exp Med Biol 2003, 532:215-221.
58. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010, 9(6):1085-1099.
59. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010, 101(10):2087-2092.
60. Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., De Milito A., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009, 284(49):34211-34222.
61. Wysoczynski M., Ratajczak M.Z. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 2009, 125(7):1595-1603.
62. Qu J.L., Qu X.J., Zhao M.F., Teng Y.E., Zhang Y., Hou K.Z., et al. Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis 2009, 41(12):875-880.
63. Hendrix A., Westbroek W., Bracke M., Wever O.D. An Ex(o)citing Machinery for Invasive Tumor Growth. Cancer Res 2010, 70(23):9533-9537.
64. Riteau B., Faure F., Menier C., Viel S., Carosella E.D., Amigorena S., et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol 2003, 64(11):1064-1072.
65. Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G., Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 2007, 67(7):2912-2915.
66. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008, 15(1):80-88.
67. Ichim T.E., Zhong Z., Kaushal S., Zheng X., Ren X., Hao X., et al. J Transl Med 2008, 6:37.
68. Taylor D.D., Gerçel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005, 92(2):305-311.
69. Clayton A., Mitchell J.P., Court J., Mason M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007, 67(15):7458-7466.
70. Ashiru O., Boutet P., Fernández-Messina L., Agüera-González S., Skepper J.N., Valés-Gómez M., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010, 70(2):481-489.
71. Szajnik M., Czystowska M., Szczepanski M.J., Mandapathil M., Whiteside T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010, 5(7):e11469.
72. Abusamra A.J., Zhong Z., Zheng X., Li M., Ichim T.E., Chin J.L., et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis 2005, 35(2):169-173.
73. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009, 124(11):2621-2633.
74. André F., Schartz N.E., Chaput N., Flament C., Raposo G., Amigorena S., et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 2002, 20(Suppl 4):A28-A31.
75. Cocucci E., Racchetti G. Meldolesi J. Shedding microvesicles: artefacts no more Trends in Cell Biology 2009, 19(2):43-51.
76. Rajagopalan S., Bryceson YT., Kuppusamy SP., Geraghty DE., van der Meer A., Joosten I. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006, 4(1):e9.
77. Rouas-Freiss N., Moreau P., Menier C., LeMaoult J., Carosella E.D. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007, 17(6):413-421.
78. Avril T., Saikali S., Vauleon E., Jary A., Hamlat A., De Tayrac M., et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol 2010, 225(1-2):22-33.
79. Le Rond S., Gonzalez A., Gonzalez A.S., Carosella E.D., Rouas-Freiss N. Indoleamine 2, 3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways. Immunology 2005, 116(3):297-307.
80. González-Hernandez A., LeMaoult J., Lopez A., Alegre E., Caumartin J., Le Rond S., et al. Linking two immuno-suppressive molecules: indoleamine 2, 3 dioxygenase can modify HLA-G cell-surface expression. Biol Reprod 2005, 73(3):571-578.
81. Hayakawa S. No cancer in cancers: evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. Med Hypotheses 2006, 66(5):888-897.
82. López AS., Alegre E., LeMaoult J., Carosella E., González A. To proliferate or to divide - to be or not to be. Early Pregnancy 2001, 5(1):63-64.
83. Genbacev O. To proliferate or to divide - to be or not to be. Early Pregnancy 2001, 5(1):63-64.
84. Kilburn B.A., Wang J., Duniec-Dmuchowski Z.M., Leach R.E., Romero R., Armant D.R. Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line. Biol Reprod 2000, 62(3):739-747.
85. Bischof P., Haenggeli L., Campana A. Gelatinase and oncofetal fibronectin secretion is dependent on integrin expression on human cytotrophoblasts. Hum Reprod 1995, 10(3):734-742.
86. Hiden U., Wadsack C., Prutsch N., Gauster M., Weiss U., Frank HG., et al. The first trimester human trophoblast cell line ACH-3P: a novel tool to study autocrine/paracrine regulatory loops of human trophoblast subpopulations--TNF-alpha stimulates MMP15 expression. BMC Dev Biol 2007, 7:137.
87. Bahri R., Hirsch F., Josse A., Rouas-Freiss N., Bidere N., Vasquez A., et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 2006, 176(3):1331-1339.
88. Liu H.Y., Gu W.R., Li X.T. Effects on human leukocyte antigen-G on proliferation and invasion of JEG-3 cell line. Zhonghua Fu Chan Ke Za Zhi 2008, 43(6):445-450.
89. van der Meer A., Lukassen H.G., van Lierop M.J., Wijnands F., Mosselman S., Braat D.D., et al. Membrane-bound HLA-G activates proliferation and interferon-gamma production by uterine natural killer cells. Mol Hum Reprod 2004, 10(3):189-195.
90. Carrega P., Morandi B., Costa R., Frumento G., Forte G., Altavilla G., et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer Res 2008, 112(4):863-875.
91. Giannopoulos K., Schmitt M., Kowal M., Wlasiuk P., Bojarska-Junak A., Chen J., et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008, 20(3):677-682.
92. Giatromanolaki A., Bates G.J., Koukourakis M.I., Sivridis E., Gatter K.C., Harris A.L., et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 2008, 110(2):216-221.
93. Chen HX., Lin A., Shen CJ., Zhen R., Chen BG., Zhang X., et al. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum Immunol 2010, 71(9):892-898.
94. Cai M.Y., Xu Y.F., Qiu S.J., Ju M.J., Gao Q., Li Y.W., et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 2009, 15(14):4686-4693.